By Izi Bruker, PhD, MPH, Fellow, Clinical, Medical, and Regulatory Affairs, Kymanox Corporation

The People’s Republic of China (PRC) presents a rapidly expanding medical device market, offering immense opportunities for manufacturers and distributors with an expected growth rate of 8.3% between 2021-2026. However, navigating the intricate regulatory landscape can be challenging. To successfully enter this market, it’s crucial to stay abreast of the evolving regulations, particularly those surrounding Clinical Evaluation Reports (CERs).

Read More